Index by author

February 01, 2014; Volume 81,Issue 2

  1. Keller, David L.

    1. Canagliflozin (November 2013)
      David L. Keller, MD
      Cleveland Clinic Journal of Medicine February 2014, 81 (2) 88-90; DOI: https://doi.org/10.3949/ccjm.81c.02004

  2. Littmann, Laszlo

    1. Wide QRS complex rhythm with pulseless electrical activity
      Laszlo Littmann, MD, PhD
      Cleveland Clinic Journal of Medicine February 2014, 81 (2) 81-82; DOI: https://doi.org/10.3949/ccjm.81a.13079

      Although this presentation is grave, several of its possible causes can be treated, allowing the patient to recover.

  3. Mandell, Brian F.

    1. Should patients with gout avoid
      Brian F. Mandell, MD, PhD
      Cleveland Clinic Journal of Medicine February 2014, 81 (2) 83-86; DOI: https://doi.org/10.3949/ccjm.81a.13131

      No study has directly addressed this issue. In most cases, continue the thiazide and adjust the hypouricemic therapy if necessary.

    2. The impact of anti-TNF therapy on the nonspecialist
      Brian F. Mandell, MD, PhD
      Cleveland Clinic Journal of Medicine February 2014, 81 (2) 71-72; DOI: https://doi.org/10.3949/ccjm.81b.02014

      These drugs are being used in a growing number of diseases. We all need to increase our familiarity with their unique risks.

  4. Merugu, Srinivas

    1. In Reply: Stiff, numb hands (June 2013)
      Khaldoon Shaheen, MD and Srinivas Merugu, MD, MMM
      Cleveland Clinic Journal of Medicine February 2014, 81 (2) 87; DOI: https://doi.org/10.3949/ccjm.81c.02002

      Readers comment on the measurement of serum calcium in a patient with tetany (June 2013) and on the metabolic side effects of canagliflozin (November 2013).

  5. Rodriguez-gutierrez, René

    1. Canagliflozin (November 2013)
      René Rodríguez-Gutiérrez, MD and Gloria Gonzalez-Saldivar, MD
      Cleveland Clinic Journal of Medicine February 2014, 81 (2) 87-88; DOI: https://doi.org/10.3949/ccjm.81c.02003

      Readers comment on the measurement of serum calcium in a patient with tetany (June 2013) and on the metabolic side effects of canagliflozin (November 2013).

  6. Shaheen, Khaldoon

    1. In Reply: Stiff, numb hands (June 2013)
      Khaldoon Shaheen, MD and Srinivas Merugu, MD, MMM
      Cleveland Clinic Journal of Medicine February 2014, 81 (2) 87; DOI: https://doi.org/10.3949/ccjm.81c.02002

      Readers comment on the measurement of serum calcium in a patient with tetany (June 2013) and on the metabolic side effects of canagliflozin (November 2013).

  7. Singh, Dhssraj

    1. Anticoagulation and antiplatelet therapy in acute coronary syndromes
      Anticoagulation and antiplatelet therapy in acute coronary syndromes
      Dhssraj Singh, MD, Kamal Gupta, MD and James L. Vacek, MD, MSc
      Cleveland Clinic Journal of Medicine February 2014, 81 (2) 103-114; DOI: https://doi.org/10.3949/ccjm.81a.13016

      Antiplatelet and anticoagulant drugs prevent ischemic events but can cause bleeding. Here is how to optimize the benefit.

  8. Vacek, James L.

    1. Anticoagulation and antiplatelet therapy in acute coronary syndromes
      Anticoagulation and antiplatelet therapy in acute coronary syndromes
      Dhssraj Singh, MD, Kamal Gupta, MD and James L. Vacek, MD, MSc
      Cleveland Clinic Journal of Medicine February 2014, 81 (2) 103-114; DOI: https://doi.org/10.3949/ccjm.81a.13016

      Antiplatelet and anticoagulant drugs prevent ischemic events but can cause bleeding. Here is how to optimize the benefit.

  9. Vouyiouklis, Mary

    1. In Reply: Canagliflozin (November 2013)
      Mary Vouyiouklis, MD
      Cleveland Clinic Journal of Medicine February 2014, 81 (2) 90; DOI: https://doi.org/10.3949/ccjm.81c.02005

  10. Wasko, Mary Chester

    1. Managing risks of TNF inhibitors: An update for the internist
      Jennifer Hadam, MD, Elie Aoun, MD, MS, Kofi Clarke, MD and Mary Chester Wasko, MD, MSc
      Cleveland Clinic Journal of Medicine February 2014, 81 (2) 115-127; DOI: https://doi.org/10.3949/ccjm.81a.12121

      Tumor necrosis factor inhibitors pose infrequent but serious risks, including infection and malignancy.

« Previous (Pages : 1 2 3 ... 3) Next »
Back to top

In this issue